PET for Evaluation of Neurologic Diseases: Part one: Neurodegenerative Diseases
Related Experiment Video
Updated: Oct 31, 2026

A Behavioral Test Battery for the Repeated Assessment of Motor Skills, Mood, and Cognition in Mice
Published on: March 2, 2019
Eren Veziroglu1, Moozhan Nikpanah2, Faraz Farhadi3
1Department of Radiology, University of Alabama at Birmingham, Heersink School of Medicine, Birmingham, AL, USA; Institute of Nuclear Medicine, Bethesda, MD, USA.
Abstract:
This review of PET for evaluation of neurological diseases is divided into two parts; part one examines the clinical use of positron emission tomography (PET) in neurodegenerative diseases. FDG-PET can identify characteristic patterns of cerebral metabolism and help distinguish among neurodegenerative disorders. Amyloid and tau PET have expanding diagnostic and theranostic roles in Alzheimer's disease, including assessment of disease-specific pathology and treatment eligibility. FDOPA-PET evaluates presynaptic dopamine synthesis and supports assessment of Parkinson's disease and other parkinsonian syndromes. Combined with structural imaging and clinical evaluation, PET can improve diagnostic confidence, refine prognosis, and inform treatment decisions.
Related Concept Videos
Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Parkinson's Disease: Overview
Parkinson Disease l: Introduction
Alzheimer Disease ll: Pathophysiology
Alzheimer Disease l: Introduction
Dementia l: Introduction

